NASDAQ:MNPR Monopar Therapeutics Q2 2025 Earnings Results & Report $73.10 +1.02 (+1.42%) Closing price 04:00 PM EasternExtended Trading$73.13 +0.03 (+0.04%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Monopar Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.35 versus the -$0.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call8:15 AM ET Monopar Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.47Beat/MissBeat by +$0.12One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersMonopar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMonopar Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monopar Therapeutics Q2 2025 Earnings FAQ Did Monopar Therapeutics beat earnings estimates for Q2 2025? Monopar Therapeutics (NASDAQ:MNPR) reported earnings of -$0.35 per share for Q2 2025, beating the consensus estimate of -$0.47. The report was announced on Tuesday, August 12, 2025. When is Monopar Therapeutics' next earnings date? Monopar Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Monopar Therapeutics on the company's earnings history page. Monopar Therapeutics Earnings HeadlinesMonopar Therapeutics Inc. (NASDAQ:MNPR) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesOctober 11 at 2:15 AM | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Cut to "Sell" at Wall Street ZenOctober 10, 2026 | americanbankingnews.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 14 at 1:00 AM | Brownstone Research (Ad)Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Christopher Starr Sells 8,400 SharesOctober 7, 2026 | americanbankingnews.comMonopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC FilingOctober 5, 2026 | marketscreener.comMPiper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)September 29, 2026 | theglobeandmail.comSee More Monopar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monopar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monopar Therapeutics and other key companies, straight to your email. Email Address About Monopar TherapeuticsMonopar Therapeutics (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies. Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers. These programs include radiopharmaceutical applications intended to help identify or treat tumors expressing uPAR. Monopar was founded in 2014 and is headquartered in Wilmette, Illinois. Its activities are primarily focused on clinical development and collaborations within the oncology and radiopharmaceutical sectors, with potential applications for patients in the United States and other international markets. Chandler Robinson has served as the company’s chief executive officer and has been involved in its development since its early stages.View Monopar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
